GNPX

Genprex, Inc. (GNPX) - Q2 2025 10-Q Summary

Business Context and Reporting Period

Genprex, Inc. is a clinical-stage gene therapy company focused on oncology (REQORSA) and diabetes (GPX-002) programs. This report covers the quarterly period ended June 30, 2025. The company operates as a single segment and is currently incurring significant losses while advancing clinical trials. As of August 1, 2025, there were 33,466,784 shares of common stock outstanding.

Key Financial Metrics

Liquidity: The company reported a working capital deficit of approximately $380,000 ($2.06M current assets vs. $2.44M current liabilities) as of June 30, 2025. Management estimates current cash will fund operations through the end of August 2025.

Material Changes vs. Prior Period

• Expense Reduction: Net loss decreased by 31% year-over-year for the six-month period, primarily due to the closure of the Acclaim-2 clinical trial and significant expense reduction strategies (reduced headcount from 21 to 15 employees, lower travel, and fewer professional service providers).
• General & Administrative (G&A): G&A expenses dropped 52% year-over-year (from $7.57M to $3.61M) due to the aforementioned cost-cutting measures.
• Research & Development (R&D): R&D expenses increased slightly by 2% year-over-year (from $4.94M to $5.04M). This increase is attributed to the absence of a $1.165M one-time refund from a contract manufacturer recorded in the prior year, offset by reduced clinical expenses from closing the Acclaim-2 trial.
• Capital Structure: The company significantly increased its share count, issuing over 22 million shares in the first half of 2025 through its ATM facility and a new Equity Line of Credit (ELOC), compared to approximately 1 million shares in the same period in 2024.

Guidance, Outlook, and Risks

• Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing. No adjustments have been made to asset recoverability or liability classification.
• Capital Raising: The company entered a $12.5M ELOC with Lincoln Park Capital in June 2025. As of the filing date, the company has utilized the full 19.99% exchange cap (5.56M shares) allowed under Nasdaq rules without shareholder approval. Further sales require shareholder approval or meeting specific average price conditions.
• Nasdaq Compliance: The company received notice from Nasdaq on August 12, 2025, regarding potential delisting due to failure to maintain the $1.00 minimum bid price requirement. The company intends to request a hearing and may consider a reverse stock split.
• Clinical Outlook:
  • Acclaim-1 (NSCLC): Phase 2a expansion is enrolling ~33 patients; interim analysis expected in H1 2026.
  • Acclaim-3 (SCLC): Phase 2 expansion is enrolling ~50 patients; interim analysis expected in Q1 2026.
  • Acclaim-2: Enrollment ceased in August 2024.
  • Diabetes: Preclinical studies ongoing; seeking FDA guidance for IND-enabling studies in H2 2025.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting, citing a lack of segregation of duties and insufficient accounting personnel depth.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to secure funding immediately, as management projects cash sufficiency only through August 2025.
• Shareholder Approval: Monitor the outcome of the upcoming 2025 Annual Meeting regarding the approval to exceed the ELOC exchange cap.
• Nasdaq Status: Track the status of the hearing request regarding the $1.00 bid price delisting notice and any potential reverse stock split announcements.
• Internal Controls: Review the progress of remediation efforts for the identified material weaknesses in financial reporting.
• Clinical Milestones: Confirm enrollment rates for Acclaim-1 and Acclaim-3 trials to ensure they meet the Q1 2026 interim analysis targets.